Last checked at 
LONDON (Alliance News) - Angle PLC on Wednesday announced positive results from a study evaluating the ability of its Parsortix and HyCEAD Ziplex platforms to test for ovarian cancer.
The clinical verification study was designed to test Angle's two platforms "as a simple blood test to detect the presence of ovarian cancer in women with a pelvic mass" using clinical samples.
The study involved the evaluation 26 stage three and four ovarian cancer patients and 28 healthy volunteers. Parsortix harvested circulating tumour cells from the blood and then HyCEAD-Ziplex was used to analyse those cells.
In combination, the platforms were able to discriminate between healthy volunteers and cancer patients, suggesting they could be used to correctly detect cancer and are unlikely to give a false positive.
Angle is now planning a new 200-subject ovarian cancer clinical verification study of patients with a pelvic mass who are scheduled to undergo surgery. The study is set to begin in the third quarter of 2019 and complete in the first quarter of 2020. This follows a previous 200-subject study which also had a positive outcome.
Angle Founder & Chief Executive Andrew Newland said: "The performance of Angle's optimised sample-to-answer molecular solution for ovarian cancer in the pre-study is encouraging. We are excited about progressing the full clinical verification study which will help support the launch of a clinical assay at a clinical laboratory and/or via a commercial partnership."
Shares in Angle were down 2.2% at 67.99 pence on Wednesday afternoon.
